Aims To determine long-term efficacy of riboflavin/ultraviolet A corneal cross-linking (CXL). Methods Thirty patients (30 eyes) who had undergone CXL following epithelial removal 4–6 years previously were examined. Results At 1-year mean, spherical equivalent error (SEQ) increased by +0.72 dioptres (D) (pConclusions CXL is an effective and safe treatment with up to 4–6 years follow-up. Improvements in topographic and wave-front parameters evident at 1 year continue to improve at 4–6 years.